MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer

Menno R. Vriens, Julie Weng, Insoo Suh, Nhung Huynh, Marlon A Guerrero, Wen T. Shen, Quan Yang Duh, Orlo H. Clark, Electron Kebebew

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

BACKGROUND: Approximately 30% of fine-needle aspiration (FNA) biopsies of thyroid nodules are indeterminate or nondiagnostic. Recent studies suggest microRNA (miRNA, miR) is differentially expressed in malignant tumors and may have a role in carcinogenesis, including thyroid cancer. The authors therefore tested the hypothesis that miRNA expression analysis would identify putative markers that could distinguish benign from malignant thyroid neoplasms that are often indeterminate on FNA biopsy. METHODS: A miRNA array was used to identify differentially expressed genes (5-fold higher or lower) in pooled normal, malignant, and benign thyroid tissue samples. Real-time quantitative polymerase chain reaction was used to confirm miRNA array expression data in 104 tissue samples (7 normal thyroid, 14 hyperplastic nodule, 12 follicular variant of papillary thyroid cancer, 8 papillary thyroid cancer, 15 follicular adenoma, 12 follicular carcinoma, 12 Hurthle cell adenoma, 20 Hurthle cell carcinoma, and 4 anaplastic carcinoma cases), and 125 indeterminate clinical FNA samples. The diagnostic accuracy of differentially expressed genes was determined by analyzing receiver operating characteristics. RESULTS: Ten miRNAs showed >5-fold expression difference between benign and malignant thyroid neoplasms on miRNA array analysis. Four of the 10 miRNAs were validated to be significantly differentially expressed between benign and malignant thyroid neoplasms by quantitative polymerase chain reaction (P <.002): miR-100, miR-125b, miR-138, and miR-768-3p were overexpressed in malignant samples of follicular origin (P <.001), and in Hurthle cell carcinoma samples alone (P <.01). Only miR-125b was significantly overexpressed in follicular carcinoma samples (P <.05). The accuracy for distinguishing benign from malignant thyroid neoplasms was 79% overall, 98% for Hurthle cell neoplasms, and 71% for follicular neoplasms. The miR-138 was overexpressed in the FNA samples (P =.04) that were malignant on final pathology with an accuracy of 75%. CONCLUSIONS: MicroRNA expression differs for normal, benign, and malignant thyroid tissue. Expression analysis of differentially expressed miRNA could help distinguish benign from malignant thyroid neoplasms that are indeterminate on thyroid FNA biopsy.

Original languageEnglish (US)
Pages (from-to)3426-3432
Number of pages7
JournalCancer
Volume118
Issue number13
DOIs
StatePublished - Jul 1 2012

Fingerprint

MicroRNAs
Thyroid Neoplasms
Oxyphil Cells
Fine Needle Biopsy
Carcinoma
Thyroid Gland
Adenoma
Neoplasms
Thyroid Nodule
ROC Curve
Genes
Real-Time Polymerase Chain Reaction
Carcinogenesis
Pathology
Polymerase Chain Reaction

Keywords

  • Biomarker
  • Cancer
  • Diagnostic
  • MicroRNA
  • Thyroid

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vriens, M. R., Weng, J., Suh, I., Huynh, N., Guerrero, M. A., Shen, W. T., ... Kebebew, E. (2012). MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer, 118(13), 3426-3432. https://doi.org/10.1002/cncr.26587

MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. / Vriens, Menno R.; Weng, Julie; Suh, Insoo; Huynh, Nhung; Guerrero, Marlon A; Shen, Wen T.; Duh, Quan Yang; Clark, Orlo H.; Kebebew, Electron.

In: Cancer, Vol. 118, No. 13, 01.07.2012, p. 3426-3432.

Research output: Contribution to journalArticle

Vriens, MR, Weng, J, Suh, I, Huynh, N, Guerrero, MA, Shen, WT, Duh, QY, Clark, OH & Kebebew, E 2012, 'MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer', Cancer, vol. 118, no. 13, pp. 3426-3432. https://doi.org/10.1002/cncr.26587
Vriens, Menno R. ; Weng, Julie ; Suh, Insoo ; Huynh, Nhung ; Guerrero, Marlon A ; Shen, Wen T. ; Duh, Quan Yang ; Clark, Orlo H. ; Kebebew, Electron. / MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. In: Cancer. 2012 ; Vol. 118, No. 13. pp. 3426-3432.
@article{c503ef79ea8c4088b4e68690a6f57400,
title = "MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer",
abstract = "BACKGROUND: Approximately 30{\%} of fine-needle aspiration (FNA) biopsies of thyroid nodules are indeterminate or nondiagnostic. Recent studies suggest microRNA (miRNA, miR) is differentially expressed in malignant tumors and may have a role in carcinogenesis, including thyroid cancer. The authors therefore tested the hypothesis that miRNA expression analysis would identify putative markers that could distinguish benign from malignant thyroid neoplasms that are often indeterminate on FNA biopsy. METHODS: A miRNA array was used to identify differentially expressed genes (5-fold higher or lower) in pooled normal, malignant, and benign thyroid tissue samples. Real-time quantitative polymerase chain reaction was used to confirm miRNA array expression data in 104 tissue samples (7 normal thyroid, 14 hyperplastic nodule, 12 follicular variant of papillary thyroid cancer, 8 papillary thyroid cancer, 15 follicular adenoma, 12 follicular carcinoma, 12 Hurthle cell adenoma, 20 Hurthle cell carcinoma, and 4 anaplastic carcinoma cases), and 125 indeterminate clinical FNA samples. The diagnostic accuracy of differentially expressed genes was determined by analyzing receiver operating characteristics. RESULTS: Ten miRNAs showed >5-fold expression difference between benign and malignant thyroid neoplasms on miRNA array analysis. Four of the 10 miRNAs were validated to be significantly differentially expressed between benign and malignant thyroid neoplasms by quantitative polymerase chain reaction (P <.002): miR-100, miR-125b, miR-138, and miR-768-3p were overexpressed in malignant samples of follicular origin (P <.001), and in Hurthle cell carcinoma samples alone (P <.01). Only miR-125b was significantly overexpressed in follicular carcinoma samples (P <.05). The accuracy for distinguishing benign from malignant thyroid neoplasms was 79{\%} overall, 98{\%} for Hurthle cell neoplasms, and 71{\%} for follicular neoplasms. The miR-138 was overexpressed in the FNA samples (P =.04) that were malignant on final pathology with an accuracy of 75{\%}. CONCLUSIONS: MicroRNA expression differs for normal, benign, and malignant thyroid tissue. Expression analysis of differentially expressed miRNA could help distinguish benign from malignant thyroid neoplasms that are indeterminate on thyroid FNA biopsy.",
keywords = "Biomarker, Cancer, Diagnostic, MicroRNA, Thyroid",
author = "Vriens, {Menno R.} and Julie Weng and Insoo Suh and Nhung Huynh and Guerrero, {Marlon A} and Shen, {Wen T.} and Duh, {Quan Yang} and Clark, {Orlo H.} and Electron Kebebew",
year = "2012",
month = "7",
day = "1",
doi = "10.1002/cncr.26587",
language = "English (US)",
volume = "118",
pages = "3426--3432",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "13",

}

TY - JOUR

T1 - MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer

AU - Vriens, Menno R.

AU - Weng, Julie

AU - Suh, Insoo

AU - Huynh, Nhung

AU - Guerrero, Marlon A

AU - Shen, Wen T.

AU - Duh, Quan Yang

AU - Clark, Orlo H.

AU - Kebebew, Electron

PY - 2012/7/1

Y1 - 2012/7/1

N2 - BACKGROUND: Approximately 30% of fine-needle aspiration (FNA) biopsies of thyroid nodules are indeterminate or nondiagnostic. Recent studies suggest microRNA (miRNA, miR) is differentially expressed in malignant tumors and may have a role in carcinogenesis, including thyroid cancer. The authors therefore tested the hypothesis that miRNA expression analysis would identify putative markers that could distinguish benign from malignant thyroid neoplasms that are often indeterminate on FNA biopsy. METHODS: A miRNA array was used to identify differentially expressed genes (5-fold higher or lower) in pooled normal, malignant, and benign thyroid tissue samples. Real-time quantitative polymerase chain reaction was used to confirm miRNA array expression data in 104 tissue samples (7 normal thyroid, 14 hyperplastic nodule, 12 follicular variant of papillary thyroid cancer, 8 papillary thyroid cancer, 15 follicular adenoma, 12 follicular carcinoma, 12 Hurthle cell adenoma, 20 Hurthle cell carcinoma, and 4 anaplastic carcinoma cases), and 125 indeterminate clinical FNA samples. The diagnostic accuracy of differentially expressed genes was determined by analyzing receiver operating characteristics. RESULTS: Ten miRNAs showed >5-fold expression difference between benign and malignant thyroid neoplasms on miRNA array analysis. Four of the 10 miRNAs were validated to be significantly differentially expressed between benign and malignant thyroid neoplasms by quantitative polymerase chain reaction (P <.002): miR-100, miR-125b, miR-138, and miR-768-3p were overexpressed in malignant samples of follicular origin (P <.001), and in Hurthle cell carcinoma samples alone (P <.01). Only miR-125b was significantly overexpressed in follicular carcinoma samples (P <.05). The accuracy for distinguishing benign from malignant thyroid neoplasms was 79% overall, 98% for Hurthle cell neoplasms, and 71% for follicular neoplasms. The miR-138 was overexpressed in the FNA samples (P =.04) that were malignant on final pathology with an accuracy of 75%. CONCLUSIONS: MicroRNA expression differs for normal, benign, and malignant thyroid tissue. Expression analysis of differentially expressed miRNA could help distinguish benign from malignant thyroid neoplasms that are indeterminate on thyroid FNA biopsy.

AB - BACKGROUND: Approximately 30% of fine-needle aspiration (FNA) biopsies of thyroid nodules are indeterminate or nondiagnostic. Recent studies suggest microRNA (miRNA, miR) is differentially expressed in malignant tumors and may have a role in carcinogenesis, including thyroid cancer. The authors therefore tested the hypothesis that miRNA expression analysis would identify putative markers that could distinguish benign from malignant thyroid neoplasms that are often indeterminate on FNA biopsy. METHODS: A miRNA array was used to identify differentially expressed genes (5-fold higher or lower) in pooled normal, malignant, and benign thyroid tissue samples. Real-time quantitative polymerase chain reaction was used to confirm miRNA array expression data in 104 tissue samples (7 normal thyroid, 14 hyperplastic nodule, 12 follicular variant of papillary thyroid cancer, 8 papillary thyroid cancer, 15 follicular adenoma, 12 follicular carcinoma, 12 Hurthle cell adenoma, 20 Hurthle cell carcinoma, and 4 anaplastic carcinoma cases), and 125 indeterminate clinical FNA samples. The diagnostic accuracy of differentially expressed genes was determined by analyzing receiver operating characteristics. RESULTS: Ten miRNAs showed >5-fold expression difference between benign and malignant thyroid neoplasms on miRNA array analysis. Four of the 10 miRNAs were validated to be significantly differentially expressed between benign and malignant thyroid neoplasms by quantitative polymerase chain reaction (P <.002): miR-100, miR-125b, miR-138, and miR-768-3p were overexpressed in malignant samples of follicular origin (P <.001), and in Hurthle cell carcinoma samples alone (P <.01). Only miR-125b was significantly overexpressed in follicular carcinoma samples (P <.05). The accuracy for distinguishing benign from malignant thyroid neoplasms was 79% overall, 98% for Hurthle cell neoplasms, and 71% for follicular neoplasms. The miR-138 was overexpressed in the FNA samples (P =.04) that were malignant on final pathology with an accuracy of 75%. CONCLUSIONS: MicroRNA expression differs for normal, benign, and malignant thyroid tissue. Expression analysis of differentially expressed miRNA could help distinguish benign from malignant thyroid neoplasms that are indeterminate on thyroid FNA biopsy.

KW - Biomarker

KW - Cancer

KW - Diagnostic

KW - MicroRNA

KW - Thyroid

UR - http://www.scopus.com/inward/record.url?scp=84862530236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862530236&partnerID=8YFLogxK

U2 - 10.1002/cncr.26587

DO - 10.1002/cncr.26587

M3 - Article

C2 - 22006248

AN - SCOPUS:84862530236

VL - 118

SP - 3426

EP - 3432

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 13

ER -